Trial Profile

Phase 2 combination study of OP-1250 with palbociclib in ER+/HER2- Metastatic Breast Cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palazestrant (Primary) ; Palbociclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use

Most Recent Events

09 May 2023 According to an Olema Pharmaceuticals media release, interim results from this study will be presented at the 2023 ESMO Breast Cancer Annual Congress in Berlin, Germany, in a poster presentation on May 12, 2023.
16 Mar 2023 New trial record
09 Mar 2023 According to Olema Oncology media release, results from this study expected in the second quarter of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com